Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su‐Peng Yeh, Mehmet Ali Özcan, Steven Knapper, Jörge E. Cortes, Daniel A. Pollyea, Gert J. Ossenkoppele, Sergio Giralt, Hartmut Döhner, Michael Heuser, Liang Xiu, Indrajeet Singh, Fei Huang, Julie S. Larsen, Andrew H. Wei